Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

OBJECTIVE: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. METHODS: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Iannone, Florenzo, Trotta, Francesco, Monteccuco, Carlomaurizio, Giacomelli, Roberto, Galeazzi, Mauro, Matucci‐Cerinic, Marco, Ferri, Clodoveo, Cutolo, Maurizio, Bambara, Lisa Maria, Triolo, Giovanni, Ferraccioli, Gianfranco, Valentini, Gabriele, Lapadula, Giovanni
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2007
Teme:
Concise Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798487/
https://ncbi.nlm.nih.gov/pubmed/16837489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.058776
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items